GRAIL (NASDAQ:GRAL) Insider Andrew John Partridge Sells 7,873 Shares of Company Stock

GRAIL, Inc. (NASDAQ:GRAL) insider Andrew Partridge sold 7,873 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $146.39, for a total value of $1,152,528.47. Following the completion of the transaction, the insider owned 155,865 shares of the company’s stock, valued at $22,817,077.35. This represents a 4.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

GRAIL Stock Performance

NASDAQ GRAL traded down $4.38 during trading hours on Wednesday, reaching $132.90. 992,328 shares of the company’s stock were exchanged, compared to its average volume of 980,656. The company has a market capitalization of $5.94 billion, a price-to-earnings ratio of -13.63 and a beta of 2.83. The company’s 50-day moving average is $88.31 and its two-hundred day moving average is $70.39. GRAIL, Inc. has a one year low of $41.50 and a one year high of $166.48.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.10. The firm had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. Research analysts predict that GRAIL, Inc. will post -10.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Moody National Bank Trust Division boosted its stake in shares of GRAIL by 1.3% during the 3rd quarter. Moody National Bank Trust Division now owns 13,478 shares of the company’s stock worth $1,889,000 after buying an additional 178 shares during the last quarter. Prosperity Consulting Group LLC grew its holdings in shares of GRAIL by 6.9% in the 1st quarter. Prosperity Consulting Group LLC now owns 3,881 shares of the company’s stock valued at $201,000 after acquiring an additional 250 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of GRAIL in the fourth quarter valued at about $28,000. Geneos Wealth Management Inc. increased its position in shares of GRAIL by 160.0% in the first quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock valued at $30,000 after acquiring an additional 360 shares during the last quarter. Finally, 180 Wealth Advisors LLC raised its holdings in GRAIL by 0.3% during the second quarter. 180 Wealth Advisors LLC now owns 127,774 shares of the company’s stock worth $8,723,000 after acquiring an additional 427 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on GRAL. UBS Group upped their target price on shares of GRAIL from $105.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Canaccord Genuity Group boosted their price target on GRAIL from $80.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 28th. Mizuho boosted their price target on GRAIL from $65.00 to $100.00 and gave the company a “neutral” rating in a report on Friday, September 25th. Guggenheim upped their price objective on GRAIL from $75.00 to $155.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Finally, Royal Bank Of Canada started coverage on GRAIL in a report on Thursday, September 17th. They set a “sector perform” rating and a $84.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, GRAIL currently has an average rating of “Hold” and an average price target of $102.70.

About GRAIL

GRAIL, Inc is a healthcare company focused on developing blood-based technologies for the early detection of cancer. Its goal is to identify cancer signals before symptoms appear, when treatment may be more effective, by applying genomics, machine learning and other analytical methods to blood samples.

The company’s primary product is the Galleri multi-cancer early detection test, a prescription laboratory-developed test designed to screen for signals associated with multiple types of cancer from a single blood draw.